Does MDwise Cover Dupixent?

How MDwise Handles Dupixent Coverage

MDwise provides Dupixent coverage under its pharmacy benefit for members with qualifying diagnoses, but approval is not automatic. As an Indiana Medicaid managed care organization, MDwise follows both federal Medicaid pharmacy requirements and its own formulary rules when evaluating biologic medication requests.

Indiana Medicaid law requires MCOs like MDwise to cover FDA-approved drugs when medically necessary, a standard rooted in federal Medicaid statute (42 U.S.C. § 1396r-8). MDwise places Dupixent on its specialty tier, meaning prescribers must submit a prior authorization (PA) request documenting the patient's diagnosis, treatment history, and disease severity. The PA process typically takes 3 to 5 business days for standard requests.

Dupixent gained its first FDA approval in March 2017 for adults with moderate-to-severe atopic dermatitis. Since then, the FDA has expanded its indications six times, most recently adding COPD with an eosinophilic phenotype in September 2024. MDwise evaluates coverage for each indication separately, and approval criteria may differ depending on the specific condition being treated.

Members enrolled in the Hoosier Healthwise, Healthy Indiana Plan (HIP), or Hoosier Care Connect programs through MDwise can all potentially access Dupixent if clinical criteria are met. The plan does not distinguish between these enrollment pathways when applying its PA criteria for biologics.

Prior Authorization Requirements for Dupixent Through MDwise

Getting Dupixent approved through MDwise requires documentation that the patient meets specific clinical thresholds. The PA form must be completed by the prescribing physician and submitted to MDwise pharmacy services.

For atopic dermatitis, MDwise generally requires evidence of moderate-to-severe disease, often defined by an Investigator Global Assessment (IGA) score of 3 or higher, or body surface area (BSA) involvement of 10% or greater. These benchmarks align with criteria used in the SOLO 1 and SOLO 2 registration trials, where dupilumab 300 mg every two weeks produced IGA 0/1 responses in 36% to 38% of adults at week 16, compared with 8% to 10% on placebo [1]. The prescriber should document the IGA score, BSA percentage, and a description of how the disease affects daily functioning.

For moderate-to-severe asthma, MDwise requires documentation of an eosinophilic phenotype (blood eosinophils of 150 cells/µL or higher) or oral corticosteroid dependence. In the LIBERTY ASTHMA QUEST trial (N=1,902), dupilumab reduced annualized severe exacerbation rates by 47.7% in the overall population and by 65.8% in patients with baseline eosinophils of 300 cells/µL or greater [2].

For chronic rhinosinusitis with nasal polyps (CRSwNP), prescribers must document failure of intranasal corticosteroids and often prior sinus surgery or contraindication to surgery. The SINUS-24 trial showed a mean reduction in nasal polyp score of 1.89 points with dupilumab versus 0.17 with placebo at 24 weeks (P<0.001) [3].

Step Therapy: What You Must Try First

MDwise requires step therapy before approving Dupixent, meaning patients must try and fail less expensive treatments. This is standard practice among Medicaid MCOs.

For atopic dermatitis, the typical step therapy sequence includes topical corticosteroids (medium to high potency), topical calcineurin inhibitors such as tacrolimus or pimecrolimus, and in many cases a trial of systemic immunosuppressants like methotrexate, cyclosporine, or mycophenolate. MDwise usually requires documented failure of, intolerance to, or contraindication for at least one systemic agent before approving dupilumab. "Failure" generally means inadequate response after 8 to 12 weeks of therapy at appropriate doses.

For asthma, step therapy typically requires failure of inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination therapy at medium-to-high doses. MDwise may also require trial of a long-acting muscarinic antagonist (LAMA) add-on.

The American Academy of Dermatology 2024 guidelines recommend dupilumab as a first-line systemic therapy for moderate-to-severe atopic dermatitis, positioning it ahead of conventional immunosuppressants based on its superior safety profile [4]. Dr. Jonathan Silverberg, a dermatologist at George Washington University and co-author of the AAD guidelines, has stated: "Dupilumab has changed how we think about sequencing therapy in atopic dermatitis. The data supporting its long-term safety over three years is stronger than what we have for any conventional systemic agent in this disease."

If your prescriber believes step therapy is medically inappropriate, they can request a step therapy override by submitting clinical rationale explaining why the required medications are contraindicated or likely to be ineffective based on the patient's history.

What Dupixent Costs with MDwise Coverage

Once approved, Dupixent costs through MDwise are minimal for the patient. Indiana Medicaid copayment rules cap out-of-pocket costs for most enrollees.

Hoosier Healthwise members (traditional Medicaid) typically pay $0 for prescription medications, including specialty biologics. HIP members may have nominal copays ranging from $1 to $3 depending on their income tier and the specific benefit package. No MDwise enrollee should face the full list price of Dupixent, which Sanofi lists at approximately $3,350 per syringe ($40,200 annually for the standard every-two-week regimen).

Specialty pharmacies contracted with MDwise handle Dupixent dispensing. Members usually receive their medication through a designated specialty pharmacy rather than a retail location. MDwise contracts with pharmacy benefit managers who negotiate rebates on biologic medications, though the specific rebate amounts are proprietary.

For members who face any coverage gaps or transition periods, the Dupixent MyWay copay assistance program may provide bridge supplies. Medicaid enrollees are generally ineligible for manufacturer copay cards due to federal anti-kickback statute restrictions, but Sanofi's patient assistance program can provide free drug during coverage interruptions.

How to Get Dupixent Approved: Step-by-Step Process

The path from prescription to first injection involves several concrete steps. Knowing this process helps avoid delays.

First, the prescribing dermatologist, allergist, or pulmonologist completes the MDwise PA request form. This form requires the ICD-10 diagnosis code (L20.9 for atopic dermatitis, J45.x for asthma, J33.x for nasal polyps), documentation of prior treatments tried and failed, objective severity measures, and the prescriber's clinical rationale.

Second, MDwise pharmacy services reviews the request within 3 to 5 business days for standard requests. Indiana Medicaid regulations require a decision within 24 hours for urgent/expedited requests when delay could seriously jeopardize the patient's health.

Third, if approved, MDwise issues an authorization number and notifies the specialty pharmacy. The authorization period is typically 6 to 12 months, after which reauthorization is needed with updated clinical documentation showing continued medical necessity.

Fourth, the specialty pharmacy contacts the patient to arrange delivery and provide injection training. Dupixent is administered subcutaneously every two weeks (300 mg for adults with atopic dermatitis) or every two weeks with a 600 mg loading dose on day one. For children aged 6 months to 5 years with atopic dermatitis weighing 5 kg to <15 kg, the dose is 200 mg every four weeks per FDA labeling.

What to Do If MDwise Denies Your Dupixent Request

A denial is not the end of the road. MDwise members have multiple appeal options, and denial overturn rates for biologic medications tend to be meaningful when appeals include strong clinical documentation.

When MDwise denies a PA request, the denial letter must specify the reason. Common reasons include incomplete documentation, failure to complete required step therapy, or a determination that the requested indication does not meet coverage criteria. The denial letter also outlines appeal rights and deadlines.

Standard appeals must be filed within 30 calendar days of the denial notice. The appeal should include a letter from the prescriber addressing the specific denial reason, any new clinical data (lab results, photographs of skin disease, pulmonary function tests), peer-reviewed literature supporting the request, and a clear explanation of why alternative treatments are inadequate.

If the standard appeal is denied, members can request a State Fair Hearing through the Indiana Family and Social Services Administration (FSSA). This independent review process is a right guaranteed under federal Medicaid regulations (42 CFR § 431.200) [5].

For urgent situations, expedited appeals must be resolved within 72 hours. The prescriber should indicate that delay poses an immediate risk, such as severe disease flare, risk of hospitalization, or rapid deterioration.

An Indiana-specific consideration: MDwise must follow the state's Medicaid preferred drug list (PDL), managed by the Indiana Drug Utilization Review Board. If dupilumab is listed as preferred for a given indication on the Indiana PDL, MDwise has less discretion to deny coverage and PA requirements may be simplified.

Dupixent Coverage for Children Through MDwise

Pediatric coverage through MDwise follows the same general PA framework as adult coverage, but with age-specific considerations that prescribers should address in the authorization request.

The FDA has approved dupilumab for atopic dermatitis in patients as young as 6 months. The phase 3 trial in children aged 6 months to 5 years (N=162) demonstrated that 28% of dupilumab-treated patients achieved IGA 0/1 at week 16, compared with 4% on placebo [6]. Weight-based dosing applies for this age group.

For children aged 6 to 11 years, dosing is weight-based: 200 mg every two weeks for patients weighing 15 kg to <60 kg, and 300 mg every two weeks for patients weighing 60 kg or more. The AD-1652 trial in this age group showed 33.2% IGA 0/1 response versus 11.4% placebo [7].

Indiana Medicaid provides Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) coverage for children under 21. Under EPSDT, coverage requirements are broader than for adults. If dupilumab is medically necessary for a child's condition, MDwise must cover it even if the drug would not be covered under adult Medicaid criteria. This federal mandate, codified in 42 U.S.C. § 1396d(r), gives pediatric patients a stronger legal basis for coverage.

Pediatricians or pediatric dermatologists submitting PA requests should explicitly reference EPSDT when the patient is under 21, as this can override standard formulary restrictions.

Newer FDA-Approved Indications and MDwise Coverage Timing

MDwise coverage for newer Dupixent indications may lag behind FDA approval dates. Understanding this gap helps set realistic expectations.

Dupixent received FDA approval for eosinophilic esophagitis (EoE) in May 2022 and for prurigo nodularis in September 2022. The EoE approval was based on Part A of the LIBERTY-EoE-TREET trial, where 60% of dupilumab-treated patients achieved histologic remission (peak esophageal intraepithelial eosinophil count of 6 or fewer per high-power field) at 24 weeks, versus 5% on placebo [8]. For COPD, the September 2024 approval was based on the BOREAS (N=939) and NOTUS (N=935) trials, showing 30% and 34% reductions in moderate-to-severe exacerbations, respectively [9].

When a new indication is approved, MDwise must update its formulary and PA criteria. Indiana Medicaid typically issues guidance within 90 to 180 days of a new FDA approval. During this interim period, prescribers can submit PA requests citing the new FDA-approved indication, and MDwise is required to review them on a case-by-case basis rather than issuing blanket denials.

Dr. Lisa Beck, a professor of dermatology at the University of Rochester Medical Center and principal investigator on multiple dupilumab trials, has noted: "The expansion of dupilumab into six distinct inflammatory conditions reflects its mechanism of targeting IL-4 and IL-13, two cytokines that sit at the center of type 2 inflammation across organ systems."

Comparing MDwise to Other Indiana Medicaid Plans for Dupixent

Indiana operates four Medicaid MCOs: MDwise, Anthem, CareSource, and United Healthcare Community Plan. Coverage criteria for Dupixent are broadly similar across all four because they share the Indiana PDL as a baseline.

Differences between plans tend to appear in processing speed, specialty pharmacy networks, and the specific documentation templates required for PA submission. MDwise uses its own PA form, which can be downloaded from the MDwise provider portal. Some plans accept electronic PA submissions through CoverMyMeds or similar platforms, which can reduce processing time by 1 to 2 business days.

All four Indiana MCOs are bound by the same federal and state Medicaid rules regarding formulary coverage, appeal timelines, and EPSDT requirements. The practical differences for patients are usually logistical rather than clinical. If you are choosing between Indiana Medicaid MCOs during open enrollment and anticipate needing Dupixent, contact each plan's pharmacy services department to ask about their current Dupixent PA approval rate and average processing time.

Long-Term Safety Data Supporting Coverage Decisions

Payer decisions about biologic coverage are influenced by long-term safety data, and dupilumab has accumulated more post-marketing experience than any other biologic approved for atopic dermatitis.

The LIBERTY AD OLE study followed 2,677 adults with atopic dermatitis receiving dupilumab for up to 4 years and found no new safety signals beyond the known adverse effects of injection site reactions (15.2%), conjunctivitis (8.6%), and oral herpes (3.2%) [10]. Serious infection rates were comparable to placebo-controlled periods. No increased risk of malignancy was observed.

This safety profile contrasts with conventional immunosuppressants commonly used as step therapy requirements. Cyclosporine carries risks of nephrotoxicity and hypertension with prolonged use, and the Endocrine Society and AAD recommend limiting cyclosporine to 1 to 2 years for atopic dermatitis [4]. Methotrexate requires regular hepatic and hematologic monitoring. These safety considerations support prescriber arguments for step therapy overrides when requesting dupilumab.

The FDA's post-marketing surveillance through the FAERS database has not identified any new serious risks for dupilumab through 2025, reinforcing its position as one of the better-tolerated biologics across its approved indications.